title: Integrin-linked kinase (ILK) in combination molecular targeting.
authors.affiliation: Advanced Therapeutics, BC Cancer Agency and Research Centre, Department of Pathology & Laboratory Medicine, The University of British Columbia.
authors.forename: Lincoln A
authors.initials: LA
authors.lastname: Edwards
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Shabbits
authors.forename: Marcel
authors.initials: M
authors.lastname: Bally
authors.forename: Shoukat
authors.initials: S
authors.lastname: Dedhar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002465:Cell Movement; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D015398:Signal Transduction; D000099200:Scaffold Protein ILK
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D017346:Protein Serine-Threonine Kinases; D000099200:Scaffold Protein ILK